Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Senseonics Holdings, Inc.

Senseonics develops and provides the Eversense Continuous Glucose Monitoring (CGM) System, which is a long-term implantable device designed for diabetes management.

Senseonics

Senseonics, Incorporated | 11,715 followers on LinkedIn. Creators of the first and only long-term implantable CGM | Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease.   Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring (&quot;CGM&quot;​) system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.  

The system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

Technical Executive - Engineering R&D - IoT and AI - Technology Development - Product Management - Program Management - Seeking VP, Director and Sr…

Brian Thomas

Board Member and Audit Committee Chair

Doug Prince

Leading digital innovation at the heart of science and technology

Everett Lee

Medical Device Regulatory Affairs Professional, R&D Scientist, Project and Personnel Manager

Mark Mortellaro, PhD, RAC-Devices, RCC-MDR

Senseonics, Incorporated

We are delighted to announce our new agreement with Ascensia Diabetes Care “We are extremely excited to be partnering with Ascensia, a leader in the global diabetes space. Ascensia is well known for their high-quality CONTOUR products used by more than 10 million patients world-wide to help manage their diabetes. We believe their global commercial infrastructure and commitment to the Eversense systems will drive market adoption while allowing Senseonics to focus on further development of our implanted technology.” – Tim Goodnow

Metric
Company Name	Senseonics Holdings, Inc.
Symbol	SENS
MSH ID	COM:SENSEONICS
Market	STOCKS
Sector	Healthcare
Industry	Medical - Devices
Country	US
Stage	Post-IPO Equity
Employee Count	132
Website	senseonics.com
LinkedIn	senseonics-inc
Founders

Metric
Market Cap	237.15M
Enterprise Value
Monthly Web Traffic	2.31K
Web Traffic Growth	-0.81
Valuation
Raised Capital	16M

Metric
Revenue	22.39M
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.09M
EBITDA	-74.33M
Operating Income	-75.60M
Net Income	-60.39M
EPS	-0.11
Diluted EPS	-0.11
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.14
Operating Profit Margin	-3.07
EBITDA Margin	-3.32
Net Profit Margin	-1.97
Return on Equity	-0.73
Return on Assets	-0.32
Return on Capital Employed	-0.63

COM:SENSEONICS

Senseonics

Last Close

0.32

22/11 21:00

Market Cap

237.15M

Beta: -

Volume Today

3.15M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-10.80
P/B Ratio	6.05
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	13.29
EV Multiple	-2.15

Metric
Days Sales Outstanding	63.18
Days Payables Outstanding	56.28
Days Inventory Outstanding	165.99
Operating Cycle	244.30
Cash Conversion Cycle	219.37
Asset Turnover	0.22

Metric
Operating Cash Flow	-70.16M
Free Cash Flow	-70.51M
Cash Flow to Debt	-1.19
Operating Cash Flow/Sales	-2.18
Free Cash Flow Yield	-0.26

Metric
Cash & Equivalents	75.71M
Accounts Receivable	-2.19M
Inventory	8.78M
Goodwill
Debt to Capitalization	0.58
Debt to Assets	0.31
Current Ratio	8.45
Quick Ratio	6.62

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.44
R&D to Revenue	2.49
SG&A to Revenue	0.32